The Lupus Forum
The Lupus Forum is an educational podcast developed under the auspices of the University of Leeds. It is dedicated to sharing the latest developments in lupus research, treatments, and clinical practice. The show provides continuing medical education to clinicians worldwide, aiming to improve understanding of the disease. Each episode covers relevant topics to help healthcare professionals stay updated in the field.
Episodes
Cell therapies in autoimmune disease: Emerging science and clinical potential, Highlights Podcast
Join Professor Ed Vital and Doctors Chris Wincup, Marc Scherlinger and Melanie Hagen on the Lupus Forum for their discussion of the recent webinar “Cell therapies in autoimmune disease: Emerging science and clinical potential”.
Watch them discuss key highlights from the webinar, including exploring cell therapies in lupus, focusing on their therapeutic potential, patient selection considerations
S1PR modulation: Exploring a new pathway in the treatment of lupus
Professors Ed Vital, Anca Askanase, Gavin Giovannoni and Dr Guillermo Valenzuela as they discuss key highlights from the webinar, including exploring the role of S1PR signalling in immune-mediated inflammatory diseases, the evidence supporting approved S1PR-modulating therapies, and the potential of S1PR modulation as a treatment approach for SLE.
S1PR modulation: Exploring a new pathway in the treatment of lupus, Highlights Podcast
Join Professors Ed Vital, Anca Askanase, Gavin Giovannoni and Dr Guillermo Valenzuela on the Lupus Forum for their discussion of the recent webinar “S1PR modulation: Exploring a new pathway in the treatment of lupus”.
Watch them discuss key highlights from the webinar, including exploring the role of S1PR signalling in immune-mediated inflammatory diseases, the evidence supporting approved S1PR-
Guiding lupus clinical management: Neuropsychiatric manifestations
Tune into this episode of our 'Guiding Lupus Clinical Management' podcast series and hear from Professors Ed Vital, Maria Dall'Era and Marta Mosca as they discuss ACR and EULAR guidance on neuropsychiatric manifestations of lupus and lupus nephritis, along with what that means in practice.
Eric Morand Author Interview: August, 2026
Join Professor Ed Vital, an Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust in the UK and Professor Eric Morand, Dean of the Sub-Faculty of Clinical and Molecular Medicine at Monash University, and Head of Rheumatology at Monash Health, in Melbourne Australia, as they discuss Professor Morand’s recent paper ‘Enpatoran, a toll-like receptor 7/8 inhibitor, in moderate-to-se
Discussing Lupus: July 2026
Professor Christopher Edwards and Professor Chi-Chiu Mok discuss two recent studies advancing the treatment landscape in SLE. This episode discusses the safety of belimumab during pregnancy and the 2026 British Society for Rheumatology guideline for the management of children, young people and adults with SLE. Through expert-led discussion, this podcast offers practical perspectives for clinicians
Guiding lupus clinical management: Hematologic manifestations
Tune into this episode of our 'Guiding Lupus Clinical Management' podcast series and hear from Professors Ed Vital, Maria Dall'Era and Guillermo Pons-Estel as they discuss ACR and EULAR guidance on hematological manifestations of lupus and lupus nephritis, along with what that means in practice.
Marc Scherlinger Author Interview: June, 2026
Join Ed Vital, from the University of Leeds, United Kingdom, and Marc Scherlinger, from Strasbourg University Hospital, as they discuss his recent paper ‘Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study’.
Discussing Lupus: Emerging therapies in SLE and lupus nephritis
Dr Guillermo J. Pons-Estel and Professor Victoria Werth highlight the latest advances in lupus treatment. This podcast discusses the efficacy and safety of dapirolizumab pegol in patients with systemic lupus erythematosus, alongside new analyses demonstrating improved kidney outcomes with belimumab plus mycophenolate mofetil in lupus nephritis.
If you are interested in the papers discussed, head
Guiding lupus clinical management: The methodology behind guideline development
Tune into this episode of our 'Guiding Lupus Clinical Management' podcast series and hear from Professors Ed Vital and Maria Dall'Era as they take a closer look at the ACR and EULAR guideline development models and consider their methodological strengths and differences, and point to additional resources.
Discussing Lupus: Anifrolumab and Belimumab in Systemic Lupus Erythematosus
Professor Ed Vital and Professor Chris Edwards discuss two recent studies advancing the treatment landscape in SLE. This episode discusses real-world effectiveness of anifrolumab in moderate-to-severe SLE and belimumab in SLE with haematological manifestations. Through expert-led discussion, this podcast offers practical perspectives for clinicians looking to stay at the forefront of lupus care. T
EULAR 2026 Review Podcast
Join Professor Ed Vital as he reviews his highlights from the recent EULAR 2026 congress and discusses key abstracts and findings.
EULAR 2026 Day 4 Highlights Podcast
Join Professor Chris Edwards as he summarises his top lupus abstracts, posters, and presentations for Day 4 of EULAR 2026 (Saturday, June 6th).
EULAR 2026 Day 3 Highlights Podcast
Join Professor Chris Edwards as he summarises his top lupus abstracts, posters, and presentations for Day 3 of EULAR 2026 (Friday, June 5th).
EULAR 2026 Day 2 Highlights Podcast
Join Professor Chris Edwards as he summarises his top lupus abstracts, posters, and presentations for Day 2 of EULAR 2026 (Thursday, June 4th).
EULAR 2026 Day 1 Highlights
Join Professor Chris Edwards as he summarises his top lupus abstracts, posters, and presentations for Day 1 of EULAR 2026 (Wednesday, June 3rd).
EULAR 2026 Preview Podcast
Join Professor Chris Edwards as he previews what we are most looking forward to this EULAR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
Discussing Lupus: Antimalarial use in lupus nephritis and CAR T-cell therapy in SLE
Professor Eric Morand and Doctor Kathryn Connelly discuss two recent studies advancing the treatment landscape in SLE and lupus nephritis. This episode discusses antimalarial use and extra-renal damage accrual in lupus nephritis, as well as autologous CD19 CAR T-cell therapy for paediatric and adult SLE. Through expert-led discussion, this podcast offers practical perspectives for clinicians looki
Guiding lupus clinical management: Renal manifestations and lupus nephritis
Tune into this episode of our 'Guiding lupus clinical management' podcast series and hear from Professors Ed Vital, Liz Lightstone and Brad Rovin as they discuss ACR and EULAR guidance on renal manifestations of lupus and lupus nephritis, along with what that means in practice.
Discussing Lupus: S1PR1-mediated modulation as a treatment target, and obinutuzumab results in SLE
Professor Ed Vital and Professor Chris Edwards discuss two recent studies advancing the treatment landscape in SLE. This episode discusses S1PR1-mediated modulation of immune cell trafficking as a potential upstream therapeutic strategy in SLE, and the efficacy and safety of obinutuzumab when added to standard therapy in adults with active SLE. Through expert-led discussion, this podcast offers pr
Discussing Lupus: New Phase 2 evidence in SLE and lupus nephritis
Professor Victoria Werth and Professor Chi-Chiu Mok discuss two recent studies advancing the treatment landscape in SLE and lupus nephritis. This episode reviews findings from the Phase 2 TULIP-LN trial, highlighting how anifrolumab treatment leads to rapid reductions in urinary biomarkers of intrarenal inflammation in lupus nephritis, and discusses a single-arm Phase 2 trial evaluating daratumuma
Discussing Lupus: New treatment safety and efficacy and impact of mental health outcomes in SLE
Professor Victoria Werth and Doctor Guillermo J. Pons-Estel highlights the new treatment safety and efficacy and impact of mental health outcomes in SLE. This podcast discusses efficacy and safety of SC anifrolumab in SLE, and the associations between discrimination and PROs and the role of mental health in these associations among a multiracial, multiethnic cohort with SLE. If you are interested
Discussing Lupus: CM313 and predictors of damage in accrual in SLE
Professor Ed Vital discusses two key publications covered on the Lupus Forum in December. his podcast reviews data from a randomised, double-blind, placebo-controlled Phase Ib/IIa trial of the anti-CD38 monoclonal antibody CM313 in adults with systemic lupus erythematosus (SLE), focusing on safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy. The epi
Discussing Lupus: Belimumab and CD19 CAR NK-cell therapy in systemic lupus erythematosus
Professor Richard Furie and Doctor Guillermo J. Pons-Estel review two key publications covered on the Lupus Forum in November. This podcast reports data from a multicentre, randomised, double-blind, placebo-controlled trial evaluating low-dose belimumab in patients with systemic lupus erythematosus (SLE), with a focus on disease flare prevention. The episode also reports findings on the efficacy a
Discussing Lupus: Emerging treatments in SLE and LN
Professor Vibeke Strand highlights the emerging treatments in SLE and LN. This podcast reports the efficacy and safety results of a Phase 3 trial of telitacicept at a dose of 160mg weekly as compared with PBO in Chinese persons with active SLE. The efficacy and safety of SC secukinumab 300mg compared with PBO, in combination with the SoC, in patients with active LN is also reported.
If you are i
Early Use of Advanced Therapies in Lupus: Highlights Podcast
Join Professor Ed Vital, Dr Guillermo J. Pons-Estel, Professor Richard Furie and Professor Chris Edwards on the Lupus Forum for their discussion of the recent webinar “Early use of advanced therapies in lupus”. Watch them discuss key highlights from the webinar, including limitations of SoC, insights from clinical trials and strategies for early intervention with advanced therapies.
Visit www.lup
Lupus at ACR 2025: Review Podcast
Join Professors Ed Vital and Maria Dall'Era as they review their highlights of the recent ACR 2025 congress, watch them discuss their abstracts and highlight key information.
ACR 2025 Highlights: Day 4
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 4 of ACR 2025 (Wednesday, October 29th).
ACR 2025 Highlights: Day 3
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 3 of ACR 2025 (Tuesday, October 28th).
ACR 2025 Highlights: Day 2
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 2 of ACR 2025 (Monday, October 27th).
ACR 2025 Highlights: Day 1
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 1 of ACR 2025 (Sunday, October 26th).
Discussing Lupus: EULAR recommendations and long-term efficacy/safety of JAKis or BTKs
Join Professor Chris Edwards and Doctor Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and efficacy and safety of upadacitinib as a monotherapy or combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE, and also supporting clinical care, translational/observation research.
If you are interested in the
Lupus at ACR 2025: Preview Podcast
Join Professors Ed Vital and Maria Dall'Era as they preview what they are most looking forward to this ACR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
Discussing Lupus: Therapeutic strategies and emerging treatments in SLE and LN
Professor Eric Morand and Professor Rangi Kandane-Rathnayake discuss the therapeutic strategies and emerging treatments in SLE and LN. This podcast provides a valuable framework for guiding therapeutic decisions for rare SLE manifestations where the available recommendations might be insufficient or inapplicable. The efficacy, PK and safety of iscalimab versus placebo as add-on to SoC therapy in p
Discussing Lupus: Emerging therapies and renal outcomes in LN
Join Professor Brad Rovin for an expert-led discussion focused on emerging therapies and renal outcomes in LN. This podcast will provide an overview of the effect of long-term voclosporin treatment on renal histology in patients with active LN with repeat renal biopsies, and explore how BCMA-targeted CAR T-cell therapy can effectively induce disease remission in refractory LN.
If you are interes
Discussing Lupus: 2025 ACR Guideline for the Treatment of SLE
Join Professors Ed Vital and Maria Dall’Era, and Doctor Guillermo J. Pons-Estel for an expert-led discussion focusing on the latest ACR 2025 SLE Guidelines. This podcast provides an overview of the latest treatment recommendations, as well as ungraded, consensus-based good practice statements that are applicable to children and adults with SLE.
If you are interested in the paper discussed, head o
cGAS Podcast
Join Professors Ed Vital and Michelle Kahlenberg as they delve into the role of the cGAS pathway in systemic lupus erythematosus (SLE). This engaging discussion covers the pathway’s relevance in disease, recent clinical trial updates on cGAS inhibitors, and their potential role in the future treatment of SLE.
CAR-T and CAR-NK therapies: Are they the future of lupus treatment?: Highlights Podcast
Join Professor Ed Vital, and Doctors Reuben Benjamin, Chris Wincup, and Marc Scherlinger on the Lupus Forum in their discussion on the recent webinar “CAR-T and CAR-NK therapies: Are they the future of lupus treatment?”. Watch them discuss key highlights from the webinar including the potential of CAR-T and CAR-NK therapies as transformative treatments for lupus. Highlighting the mechanisms, appli
Lupus at EULAR: 2025 Review Podcast
Join Professors Ed Vital and Chris Edwards as they review their highlights of the recent EULAR 2025 congress, watch them discuss their abstracts and highlight key information.
EULAR 2024 Highlights: Day 4
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 4 of EULAR 2025 (Saturday, June 14).
EULAR 2025 Highlights: Day 3
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 3 of EULAR 2025 (Friday, June 13).
Discussing Lupus: Insights into belimumab and anifrolumab in SLE
Our Steering Committee Member Professor Maria Dall’Era is joined by Professor Vibeke Strand in the latest Lupus Forum podcast. Together they discuss the efficacy of belimumab treatment in patients with SLE. They will also discuss the impact of long-term anifrolumab treatment on patients’ perceived health status and health-related quality of life.
If you are interested in the papers discussed, hea
EULAR 2025 Highlights: Day 2
Join Professor Ed Vital as he summarises his top abstracts, posters, and presentations from Day 2 of EULAR 2025 (Thursday, June 12).
EULAR 2025 Highlights: Day 1
EULAR 2025 Highlights: Day 1 by The Lupus Forum
EULAR 2025 Preview Podcast
Join Professors Ed Vital and Chris Edwards as they preview what they are most looking forward to this EULAR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
JAKi in the treatment of SLE
Join Professors Ed Vital, Cynthia Aranow, Richard Furie, and Chris Edwards as they discuss the role of the JAK-STAT pathway, the emerging evidence of using JAK Inhibitors in clinical trials (SLEek trial), and the need for long-term data and the challenges faced.
Advances in Lupus Nephritis Podcast
Join Professors Liz Lightstone and Maria Dall’Era for an expert-led discussion focused on lupus nephritis, exploring its current standard of care, practical implementation in clinical settings, and evolving treatment landscape. This podcast will delve into the latest advances in the management of lupus nephritis, including emerging therapies such as obinutuzumab, and examine the future treatment p
Advances in Lupus Nephritis
Join Professors Ed Vital, Brad Rovin, Liz Lightstone, and Maria Dall'Era as they review the current standard of care, the recommended guidelines, and emerging therapies in lupus nephritis. With discussions outlining strategies to improve real-world challenges in the management and overall quality of life for these patients.
Discussing Lupus: Insights into belimumab and telitacicept in SLE
Discussing Lupus: Insights into belimumab and telitacicept in SLE by The Lupus Forum
Discussing Lupus: Belimumab in mucocutaneous lupus erythematosus and anifrolumab in SLE
Our Steering Committee experts Professor Victoria Werth and Chris Edwards join the latest Lupus Forum podcast to discuss the effect of belimumab vs placebo on mucocutaneous manifestations of SLE, and the long-term impact of anifrolumab vs placebo on LLDAS and DORIS attainment in patients with SLE. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our la
Advances in SLE: Highlights Podcast
Advances in SLE: Highlights Podcast by The Lupus Forum
Discussing Lupus: Belimumab vs telitacicept post-rituximab, efficacy & safety of obinutuzumab in LN
Discussing Lupus: Belimumab vs telitacicept post-rituximab, efficacy & safety of obinutuzumab in LN by The Lupus Forum
Challenges in Lupus Nephritis Highlights Podcast
Challenges in Lupus Nephritis Highlights Podcast by The Lupus Forum
Discussing Lupus: LLDAS and remission in HDAS SLE patients and the 2024 APLAR consensus for LN
Professor Vibeke Stand (Stanford University) and Professor Eric Morand (Monash University) join the latest Lupus Forum podcast to discuss LLDAS and remission in SLE patients with HDAS, as well as the latest APLAR treatment consensus for LN.. If you are interested in the papers discussed, head on over to the Lupus Forum today! Download our latest slide decks and stay up to date with our monthly pod
Discussing Lupus: Voclosporin immunosuppressive therapy and new ACR guidelines for lupus nephritis
Steering Committee member Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the of University of California, San Francisco, USA, is joined by fellow member Professor Brad Rovin, who is Lee A. Hebert Professor of Nephrology and Medical Director at Ohio State University Clinical Research Management Institute, Columbus, Ohio, on the latest Lupus Forum podcas
Discussing Lupus: Efficacy and safety results of iberdomide in CLE, and SGLT2i vs. DPP4i in both SLE and comorbid type 2 diabetes
Steering Committee member Professor Victoria Werth, who is Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Pennsylvania, USA, is joined by fellow member Professor Chi-Chiu Mok, who is Chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong, on the latest Lupus Forum podcast.
Together, they discuss the efficacy and saf
Lupus at ACR 2024: Review Podcast
Lupus at ACR 2024: Review Podcast by The Lupus Forum
Lupus at ACR 2024: Preview Podcast
Lupus at ACR 2024: Preview Podcast by The Lupus Forum
ACR 2024 Highlights: Day 3
ACR 2024 Highlights: Day 3 by The Lupus Forum
ACR 2024 Highlights: Day 2
ACR 2024 Highlights: Day 2 by The Lupus Forum
ACR 2024 Highlights: Day 1
ACR 2024 Highlights: Day 1 by The Lupus Forum
Discussing Lupus: Defining ANA-associated arthritis and achieving treatment targets
Steering Committee members Professor Ed Vital, who is a Professor in Autoimmune Connective Tissue Diseases and Honorary Consultant Rheumatologist, at Leeds Teaching Hospitals NHS Trust, UK, is joined by Professor Richard Furie, who is Chief of the Division of Rheumatology at the Department of Medicine, Northwell Health, New York, and Professor of Medicine at the Zucker School of Medicine at Hofstr
Discussing Lupus: Sequential belimumab and rituximab treatment and CAR T-cell therapy
Steering Committee members Professor Chris Edwards from the University Hospital Southampton NHS Foundation Trust is joined by Professor Victoria Werth, from the Philadelphia Veterans Administration Hospital, Pennsylvania, USA on the latest Lupus Forum podcast.
Together, they discuss the efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients w
Rising to the challenge of inequity of outcomes in lupus treatment
Join Professors Ed Vital, Vibeke Strand, Laurent Arnaud, and Guillermo Pons-Estel as they unpack the key challenges of inequities of outcomes in lupus treatment. Providing an overview of social determinants of health in SLE, the impact of race and ancestry, and controlling disease in low and middle income country populations. You can view this video on our website here: https://lupus-forum.com/exp
Discussing Lupus: Flare Prediction and CD163 in Lupus Nephritis
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Doctor Antony Psarras, an NIHR Academic Clinical Lecturer in Rheumatology at the University of Oxford and at the Kennedy Institute of Rheumatology.
Together, they discuss the use of CD163 as a marker for diagnosis and flare in lupus nephritis. They also discuss the impact of discontinuing immunosuppression on the disease, in
July 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss the efficacy and safety of upadacitinib and elsubrutinib combination and monotherapy, as well as the association of LLDAS with improved outcomes in SL
June 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Vibeke Strand, Adjunct Clinical Professor at the Division of Immunology and Rheumatology at Stanford University School of Medicine in California. Together, they discuss predictors of belimumab renal response in lupus nephritis, and the efficacy and safety of telitacicept in SLE with haematological involvement.
Rising to the challenges of lupus trials
Join Professors Ed Vital, Richard Furie, Vibeke Strand, and Brad Rovin as they unpack the modern world of lupus clinical trials; their challenges and the potential solutions.
Lupus at EULAR: 2024 Review Podcast
With the continued release of new treatment data in lupus this podcast will highlight the key data presented at EULAR 2024. Together, our faculty discuss the latest data on CAR-T cells, rituximab, deucravacitinib, and so much more.
EULAR 2024 Highlights: Day 4
Join Professor Ed Vital as he goes through our top abstracts, posters, and presentations from Day 4 of EULAR 2024 today (Saturday 15 June). They're all available right here on the Lupus Forum YouTube channel, so make sure you don't miss them!
EULAR 2024 Highlights: Day 3
Join Professor Ed Vital as he goes through our top abstracts, posters, and presentations from Day 3 of EULAR 2024 today (Friday 14 June). They're all available right here on the Lupus Forum YouTube channel, so make sure you don't miss them!
EULAR 2024 Highlights: Day 2
Join Professor Ed Vital as he goes through our top abstracts, posters, and presentations from Day 2 of EULAR 2024 today (Thursday 13 June). They're all available right here on the Lupus Forum YouTube channel, so make sure you don't miss them!
EULAR 2024 Highlights: Day 1
Join Professor Ed Vital as he goes through our top abstracts, posters, and presentations from Day 1 of EULAR 2024 today (Wednesday 12 June). They're all available right here on the Lupus Forum YouTube channel, so make sure you don't miss them!
Lupus at EULAR: 2024 Preview Podcast
Join Professors Ed Vital and Chris Edwards as they preview our highlights this EULAR, introducing some of the top abstracts and posters we’ve chosen so that you can better plan your time at what will be a busy and exciting congress.
May 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Brad Rovin, Professor of Nephrology and Medical Director of the Ohio State University Clinical Research Management Institute. Together, they discuss the use of belimumab to reduce prednisone doses and the development of the SLESIS-R score for determining the risk of severe infection in SLE.
April 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Victoria Werth, Professor of Dermatology and Medicine, University of Pennsylvania and Philadelphia Veterans Administration Hospital. Together, they discuss the latest developments in CAR T-cell therapy, development of Smith-specific regulatory T cells, and cardiovascular risk factors.
March 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Chris Edwards, Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology University Hospital Southampton, UK. Together, they discuss the latest developments and perspectives in glucocorticoid tapering, TYK2 therapy in rheumatic disease, as well as SLE QoL and LLDAS.
February 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the University of California in San Francisco, USA. Together, they discuss latest developments and perspectives in RNase therapy and patient-reported outcome quality measures in SLE, as well as serological predictors of renal flares.Lup
January 2024 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Vibeke Strand, Adjunct Clinical Professor of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California. Together, they discuss the latest developments and perspectives in telitacicept therapy, fatigue, and disease burden.
December 2023 Monthly Publications Podcast
Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Dr Chi Chiu Mok, Chief of the Division of Rheumatology at Tuen Mun Hospital in Hong Kong. Together, they discuss the ability of obinutuzumab to preserve kidney function in patients with lupus nephritis, real-world data for telitacicept therapy, and the relationship between HCQ nonadherence and SLE disease flares.
